Neumora Therapeutics announced it will discontinue its navacaprant program after failing two additional Phase 3 trials in major depressive disorder. The Koastal-2 and Koastal-3 studies did not achieve statistical significance on their primary or key secondary endpoints, ending the late-stage development effort. In parallel with the clinical setback, Neumora said it would reduce its workforce by about 35% to achieve annual savings of $10 million, preserving cash runway into the third quarter of 2027. The company framed near-term focus around other pipeline readouts, including Alzheimer’s disease agitation, schizophrenia, and cardiometabolic programs. The decision further highlights the volatility risk in neuroscience drug development, where late-stage failures can trigger rapid operational downsizing and reallocation of investor attention.